Marginal Zone Lymphoma (MZL)
Oncology·MeSH: Lymphoma, Follicular
Prevalence
56.0 / 100K
Incidence
19.6 / 100K/yr
1 drug in development·1 company·4 clinical trials
Drug Pipeline by Phase
Phase 3(1)
Frequently asked questions
How many drugs are in development for Marginal Zone Lymphoma (MZL)?
BioSniper tracks 1 drug in development for Marginal Zone Lymphoma (MZL) across 1 company.
How many clinical trials target Marginal Zone Lymphoma (MZL)?
There are 4 clinical trials targeting Marginal Zone Lymphoma (MZL) tracked by BioSniper.
What is the prevalence of Marginal Zone Lymphoma (MZL)?
The estimated prevalence of Marginal Zone Lymphoma (MZL) is approximately 56.0 per 100,000 population.
Deep-dive into Marginal Zone Lymphoma (MZL)
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis